Market Cap : 66.97 B | Enterprise Value : 60.2 B | PE Ratio : 5.20 | PB Ratio : 3.75 |
---|
NAS:MRNA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:MRNA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Moderna has the Growth Rank of 7.
GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:
1. 5-year revenue growth rate, the higher, the better.GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.
Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.
For the Biotechnology subindustry, Moderna's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Moderna's Growth Rank distribution charts can be found below:
* The bar in red indicates where Moderna's Growth Rank falls into.
Thank you for viewing the detailed overview of Moderna's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.
Gomez Jorge M | officer: See Remarks | C/O DENTSPLY SIRONA INC 13320 BALLANTYNE CORPORATE PLACE CHARLOTTE NC 28277 |
Burton Paul | officer: Chief Medical Officer | 200 TECHNOLOGY SQUARE CAMBRIDGE MA 02139 |
Klinger Shannon Thyme | officer: Chief Legal Officer | 200 TECHNOLOGY SQUARE SUITE 300 CAMBRIDGE MA 02139 |
Le Goff Corinne | officer: Chief Commercial Officer | 200 TECHNOLOGY SQUARE SUITE 300 CAMBRIDGE MA 02139 |
Tallett Elizabeth E | director | 6705 ROCKLEDGE DR SUITE 900 BETHESDA MD 20817 |
Meline David W | officer: Chief Financial Officer | 3M COMPANY 3M OFFICE OF GENERAL COUNSEL ST PAUL MN 55144-1000 |
Horning Sandra | director | 333 LAKESIDE DRIVE FOSTER CITY CA 94404 |
Nader Francois | director | 550 HILLS DRIVE BEDMINSTER NJ 07921 |
Flagship Venturelabs Iv, Llc | 10 percent owner | 55 CAMBRIDGE PARKWAY, 8TH FLOOR CAMBRIDGE MA 02143 |
Sagan Paul | director | AKAMAI TECHNOLOGIES INC 8 CAMBRIDGE CENTER CAMBRIDGE MA 02142 |
Ruiz Israel | director | C/O FORTIVE CORPORATION 6920 SEAWAY BOULEVARD EVERETT WA 98203 |
Zaks Tal Zvi | officer: Chief Medical Officer | C/O ADAPTIMMUNE THERAPEUTICS PLC 60 JUBILEE AVE, MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RX |
Nabel Elizabeth G | director | BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS ST BOSTON MA 02115 |
Hoge Stephen | officer: President | C/O MODERNA, INC. 200 TECHNOLOGY SQUARE CAMBRIDGE MA 02139 |
Henderson Lori M. | officer: General Counsel and Secretary | MOLDFLOW CORP 430 BOSTON POST ROAD WAYLAND MA 01778 |
From GuruFocus
By ACCESSWIRE 04-04-2022
Other Sources
By Zacks 2022-03-24
By Zacks 2022-03-17
By Zacks 2022-03-30
By Zacks 2022-03-30
By Fool 2022-03-29
By Zacks 2022-03-21
By Zacks 2022-03-21
By Fool 2022-03-17
By Zacks 2022-03-30
By Fool 2022-03-24
By Zacks 2022-04-05
By Zacks 2022-03-23
By Zacks 2022-03-21
By Zacks 2022-03-22